206 related articles for article (PubMed ID: 32430981)
1. Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse.
Kim Y; Kang S; Shin H; Kim T; Yu B; Kim J; Yoo D; Jon S
Angew Chem Int Ed Engl; 2020 Aug; 59(34):14628-14638. PubMed ID: 32430981
[TBL] [Abstract][Full Text] [Related]
2. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
3. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.
Shi R; Hong L; Wu D; Ning X; Chen Y; Lin T; Fan D; Wu K
Cancer Biol Ther; 2005 Feb; 4(2):218-24. PubMed ID: 15753659
[TBL] [Abstract][Full Text] [Related]
5. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic nanovaccines sensitize EBV-associated tumors to checkpoint blockade therapy.
Liu H; Chen H; Liu Z; Le Z; Nie T; Qiao D; Su Y; Mai H; Chen Y; Liu L
Biomaterials; 2020 Oct; 255():120158. PubMed ID: 32544717
[TBL] [Abstract][Full Text] [Related]
7. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccine Displaying Immunodominant T Cell Epitopes of Fibroblast Activation Protein Is Effective Against Desmoplastic Tumors.
Shin H; Kim Y; Jon S
ACS Nano; 2023 Jun; 17(11):10337-10352. PubMed ID: 37184372
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
10. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
11. In Situ Cocktail Nanovaccine for Cancer Immunotherapy.
Liu M; Xie D; Hu D; Zhang R; Wang Y; Tang L; Zhou B; Zhao B; Yang L
Adv Sci (Weinh); 2023 Nov; 10(31):e2207697. PubMed ID: 37740439
[TBL] [Abstract][Full Text] [Related]
12. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
13. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen-Based Nanovaccine In Combination with Immune Checkpoint Inhibitors Abolish Postsurgical Tumor Recurrence and Metastasis.
Zheng P; He J; Yang Z; Fu Y; Yang Y; Li W; Ding Y; Yang X; Ma Y
Small; 2023 Dec; 19(50):e2302922. PubMed ID: 37649222
[TBL] [Abstract][Full Text] [Related]
15. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.
Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z
Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847
[TBL] [Abstract][Full Text] [Related]
16. Elastic Nanovaccine Enhances Dendritic Cell-Mediated Tumor Immunotherapy.
Li Q; Teng Z; Tao J; Shi W; Yang G; Zhang Y; Su X; Chen L; Xiu W; Yuwen L; Dong H; Mou Y
Small; 2022 Aug; 18(32):e2201108. PubMed ID: 35734820
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
18. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy.
Liu S; Wu J; Feng Y; Guo X; Li T; Meng M; Chen J; Chen D; Tian H
Bioact Mater; 2023 Apr; 22():211-224. PubMed ID: 36246666
[TBL] [Abstract][Full Text] [Related]
19. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
20. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
